DUPIXENT (Sanofi-Aventis Australia Pty Ltd)
Product name
DUPIXENT
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
196 working days (255)
Active ingredients
dupilumab (rch)
Registration type
EOI
Indication
DUPIXENT (solution for injection) is now also indicated as add on maintenance treatment in patients aged 12 years and older with moderate to severe asthma with type 2 inflammation (elevated eosinophils or elevated FeNO).
DUPIXENT is now also indicated as maintenance therapy for oral corticosteroid dependent asthma.